Trial Number



Breast Cancer

Participant Age Range

18 years and older

Participant Gender


Enrolling Participants



The Impact of Cerianna PET/CT results on the Therapeutic Decision in Patients with Known or Suspected Metastatic Breast Cancer with ER Positive and HER2 Negative Primary Lesion

This is a Phase 4, multi-center, non-randomized, open-label, prospective cohort study, with an adaptive design element to evaluate the impact of Cerianna on the management of patients by the detection of ER status in known or suspected MBC patients who receive either 1st line standard-of-care hormonal therapy or receive 2nd line standard-of-care hormonal therapy for a primary lesion characterized as ER-positive and human epidermal growth factor receptor 2 (HER2)-negative.


Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.